Biosensors International to Participate in the 30th Annual J.P. Morgan Healthcare Conference
SINGAPORE, Dec. 30, 2011 /PRNewswire-Asia/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG:SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices for interventional cardiology and critical care procedures, today announced it will be participating in the 30th Annual J.P. Morgan Healthcare Conference which will be held from 9th to 12th January 2012 in San Francisco, United States.
During this conference, the senior management of Biosensors will present on Thursday, January 12th, 2012 at 11:00am PST within the Asia Healthcare Company Track, and will also meet investors in scheduled one-on-one and small group meetings throughout the conference.
About Biosensors International Group, Ltd.
Listed on the Singapore Stock Exchange (SGX), Biosensors develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures. We aim to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation.
With the increasing use of the BioMatrix™ family of drug-eluting stents, we are rapidly emerging as a leader in the global coronary stent market. The recent launch of the Axxess™ self-expanding bifurcation drug-eluting stent and the development of the BioFreedom™ drug-coated stent will further reinforce our market position.
All three stents incorporate Biolimus A9™ (BA9™), an anti-restenotic drug developed and patented by Biosensors specifically for use with drug-eluting stents. Both the BioMatrix stent family and the Axxess stent feature a unique abluminal biodegradable polymer coating, which fully degrades into carbon dioxide and water over a six-to-nine-month period as it releases BA9. The BioMatrix stent family features workhorse stent platforms for a broad range of lesions, and the Axxess stent employs a self-expanding stent